FIXX / Here's Why Homology Medicines (FIXX) is Poised for a Turnaround After Losing 25.1% in 4 Weeks

Homology Medicines (FIXX) delivered earnings and revenue surprises of -17.65% and 23.62%, respectively, for the quarter ended December 2022. Do the nu more_horizontal

BEDFORD, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation more_horizontal

Homology Medicines (FIXX) delivered earnings and revenue surprises of 20% and 38.31%, respectively, for the quarter ended March 2022. Do the numbers h more_horizontal

Homology Medicines (FIXX) delivered earnings and revenue surprises of -1.72% and 19.80%, respectively, for the quarter ended December 2021. Do the num more_horizontal

After losing some value lately, a hammer chart pattern has been formed for Homology Medicines (FIXX), indicating that the stock has found support. Thi more_horizontal

Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal

Homology Medicines (FIXX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. more_horizontal